title: The role of nitric oxide in the transformation of visual information within the dorsal lateral geniculate nucleus of the cat.
abstract: We have shown that application of an inhibitor of the enzyme nitric oxide synthase (NOS) effectively suppresses the visual responses of relay cells in the dorsal lateral geniculate nucleus (dLGN) of the anaesthetized paralysed cat. Such suppression seems to result from a specific reduction in transmission via N-methyl-D-aspartic acid (NMDA) receptors, since iontophoretic application of the inhibitor of NOS selectively and in a dose-dependent manner decreased the responses to exogenously applied NMDA. Responses to other exogenously applied amino acid agonists, such as quisqualate (Quis), kainate (Kain) and alpha-amino-3-hydroxy-5-5-methyl-4-isoxazole-propionic acid (AMPA) were largely unaffected. Furthermore, the excitatory action of acetylcholine (ACh), normally co-localized with NOS in axonal terminals within the dLGN arising from the brainstem, was also unaffected. Unlike some other actions of nitric oxide (NO), this role seems not to involve an increase in production of cyclic guanosine-3',5'-mono-phosphate (cGMP), since application of the membrane permeable cGMP analogue 8-bromo-cGMP did not alter the suppressive effect of NOS inhibitors on either visual or NMDA evoked responses. We conclude that the normal function of NO at this level of the visual system is permissive, allowing full expression of NMDA mediated visually elicited information.
authors.affiliation: Departamento de Ciencias de la Salud I, E. U. Fisioterapia, Universidad de la Coruña, La Coruña, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Cudeiro
authors.forename: K L
authors.initials: KL
authors.lastname: Grieve
authors.forename: C
authors.initials: C
authors.lastname: Rivadulla
authors.forename: R
authors.initials: R
authors.lastname: Rodríguez
authors.forename: S
authors.initials: S
authors.lastname: Martínez-Conde
authors.forename: C
authors.initials: C
authors.lastname: Acuña
mesh_terms: D000594:Amino Acid Oxidoreductases / Q000037:antagonists & inhibitors; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D002415:Cats; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000494:pharmacology; D005829:Geniculate Bodies / Q000502:physiology*; D007478:Iontophoresis; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000502:physiology*; D019001:Nitric Oxide Synthase; D019335:Nitroarginine; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D014785:Vision, Ocular / Q000187:drug effects / Q000502:physiology*
chemical_list: D016194:Receptors, N-Methyl-D-Aspartate; D019335:Nitroarginine; C016276:8-bromocyclic GMP; D009569:Nitric Oxide; D016202:N-Methylaspartate; D001120:Arginine; D019001:Nitric Oxide Synthase; D000594:Amino Acid Oxidoreductases; D006152:Cyclic GMP